CTOs on the Move


 
Amlan International is the animal health business of Oil-Dri® Corporation of America, a leader in sorbent mineral technology. Amlan leverages Oil-Dri`s 80-plus years of mineral science expertise to develop proprietary, mineral-based feed additives that support optimal intestinal health while adding value for animal protein producers. The core of our feed additives is our natural mineral ingredient that contains high-capacity opal-CT lepispheres and undergoes proprietary thermal processing specifically tailored for each product. We also create synergistic blends of our mineral with other feed ingredients that further support normal gut function and digestive processes. Oil-Dri and the single-source mineral used in Amlan ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.amlan.com
  • 410 North Michigan Avenue Suite #400
    Chicago, IL USA 60611
  • Phone: 312.321.1515

Executives

Name Title Contact Details
Aldo Rossi
Vice President of Innovation and Technical Service Profile

Similar Companies

World Wide Webmasters

World Wide Webmasters is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Strateos

Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery.

Noxilizer

Noxilizer, Inc. provides room-temperature nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD facilities. Noxilizer’s expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process. Noxilizer, Inc., founded in 2004, is privately held with offices in the US, United Kingdom, and Japan.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.

MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.